MicroRNAs are small regulatory noncoding RNAs that regulate various biological processes associated with neurological disorders, cardiovascular diseases, cancer and viral infection. MiRNA-based therapeutics have broad applications including cancer immunotherapy, genomic engineering and protein replacement therapy. Until now, a variety of materials have been proved to be promising as non-viral nanocarriers for intracellular delivery of miRNAs, such as polymeric nanoparticles, lipid nanocapsules, and inorganic nanoparticles, etc. In this review, we will present the strategies for intracellular miRNA delivery, and specially focus on rationally designed routes, their mechanisms of action, and potential therapeutics used in the host cells or in vivo studies. Futhermore, we will also make a conclusion based on the current development. The perspective on the new generation of delivery systems toward the emerging area of miRNA-based therapeutics will be discussed as well.

Download full-text PDF

Source
http://dx.doi.org/10.1039/c8tb02946fDOI Listing

Publication Analysis

Top Keywords

non-viral nanocarriers
8
nanocarriers intracellular
8
intracellular delivery
8
mirna-based therapeutics
8
delivery
4
delivery microrna
4
therapeutics
4
microrna therapeutics
4
therapeutics micrornas
4
micrornas small
4

Similar Publications

Current approaches in CRISPR-Cas systems for diabetes.

Prog Mol Biol Transl Sci

January 2025

R and D, Salem Microbes Private Limited, Salem, Tamil Nadu, India. Electronic address:

In the face of advancements in health care and a shift towards healthy lifestyle, diabetes mellitus (DM) still presents as a global health challenge. This chapter explores recent advancements in the areas of genetic and molecular underpinnings of DM, addressing the revolutionary potential of CRISPR-based genome editing technologies. We delve into the multifaceted relationship between genes and molecular pathways contributing to both type1 and type 2 diabetes.

View Article and Find Full Text PDF

O-substituted Tertiary Amine-chitosans as Promising Nanocarriers for siRNA Delivery.

Curr Gene Ther

January 2025

Department of Chemistry and Environmental Sciences, IBILCE, São Paulo State University - UNESP, São José do Rio Preto, São Paulo, Brazil.

Introduction: The clinical translation of chitosan-based formulations for siRNA delivery has been partially limited by their poor stability/solubility at physiological conditions, although they have good biocompatibility and cost-effectiveness.

Method: In this study, the chitosan was O-substituted with diisopropylethylamine (DIPEA) groups, which improved its solubility at pH 7.4 by increasing the degree of ionization and enhanced the ability of chitosan to load siRNA at very low amine/phosphate (N/P) ratios.

View Article and Find Full Text PDF

Cancer is one of the most common diseases in developed countries. Recently, gene therapy has emerged as a promising approach to cancer treatment and has already entered clinical practice worldwide. RNA interference-based therapy is a promising method for cancer treatment.

View Article and Find Full Text PDF

Recent advances in development and delivery of non-viral nucleic acid therapeutics for brain tumor therapy.

Pharmacol Ther

February 2025

Rudolf-Boehm-Institute for Pharmacology and Toxicology, Clinical Pharmacology, Leipzig, Germany; Comprehensive Cancer Center Central Germany (CCCG), Site Leipzig, Leipzig, Germany.

Article Synopsis
  • * New research focuses on nucleic acid-based therapies that utilize molecular targets and non-viral delivery systems to offer better treatment options for HGG.
  • * The review presents the latest advances in preclinical and clinical research, covering innovative delivery methods, potential therapeutic targets, and personalized treatment approaches for HGG patients.
View Article and Find Full Text PDF

A promising approach to treat colorectal cancer (CRC) involves combining chemotherapy, epigenetics, and gene therapy to combat drug resistance. Multifunctional nanocarriers have emerged as a valuable tool for targeted CRC therapy. By delivering multiple treatments directly to cancer cells, these nanocarriers offer the potential for improved outcomes and reduced side effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!